Alzheimer’s Disease is the 6th leding cause of death. Because of this, new and inovative treatments for Alzheimer’s are not just important – they’re a necesity. If you or someone you know has been diagnosed with Alzheimer’s disease and are 55-85 years of age, you may be eligible to participate in a study designed by Merck Sharp and Dohme Corp.This study seeks to asess the safety and eficacy of an investigational drug as an adjudicative therapy to donepezil for participants with mild to moderate Alzheimer’s disease.
Study 1 - Sponsored by Janssen Immunotherapy
Who?: This study is best for patients diagnosed with mild to moderate Alzheimer's Disease, aged 55-99 years old What?: A phase II study that utilizes immunotherapy injections, in conjunction with MRI and PET Scan imagery to see if the study drug effectively clears beta-amyloid plaques that develop in the brains of patients with Alzheimer's Disease When?: 26 months, with 22 total visits to our facility Compensation?: Enrolled patients will receive $50 per visit (after the first), with a total of $1050 paid if study is completed. Compensation helps account for travel expenses and patient/caregiver's time. Chance for Placebo?: 1 out of 3 (33% Chance)
Currently enrolling for two Alzheimer's studies...
Would I Qualify?
We have different Alzheimer's studies here at Princeton Medical Institute, But In Genral you would have to qualify for he following: 1) Age: Between 50 - 90 2) You must have a medical Diagnosis of Alzheimer's disease. 3) Must have a caregiver( Facility staff member,Family member,friend, hired Professional) 4) The Study would provide you with study related clinic visits,physical examinations,lab test, as well as he study medication as no cost to you. 5) Stu1dy participation does not require insurance, nor are there any co-pays or deductibles. 6) Qualified participants will receive reasonable compensation for time and travel expenses.
...and one AAMI study
Interesting Facts: More than 5 million Americans are living with Alzheimer's. Every 66 seconds, someone in the United States develops Alzheimer's disease. Nearly half of care contributors -- those who are caregivers of someone with Alzheimer's and/or contribute financially to their care -- cut back on their own expenses (including food, transportation and medical care) to pay for dementia-related care of a family member or friend. In 2015, 15.9 million caregivers provided an estimated 18.1 billion hours of unpaid care valued at more than $221 billion. Alzheimer's is the only cause of death among the top 10 in America that cannot be prevented, cured, or even slowed. There are approximately 700,000 people dying each year because they have Alzheimer's. 1 in 3 seniors dies with Alzheimer's or another dementia
The researchers at PMI are also seeking people ages 50 through 80 who feel like their memory just isn't as good as it was when they were in their early twenties. Participants interested in this study must not have dementia or other cognitive impairment diagnosis.
Interesting Facts:
More than 5 million Americans are living with Alzheimer's.
Every 66 seconds, someone in the United States develops Alzheimer's disease.
Nearly half of care contributors -- those who are caregivers of someone with Alzheimer's and/or contribute financially to their care -- cut back on their own expenses (including food, transportation and medical care) to pay for dementia-related care of a family member or friend.
In 2015, 15.9 million caregivers provided an estimated 18.1 billion hours of unpaid care valued at more than $221 billion.
Alzheimer's is the only cause of death among the top 10 in America that cannot be prevented, cured, or even slowed.
There are approximately 700,000 people dying each year because they have Alzheimer's.
1 in 3 seniors die with some form of Alzheimer's or Dementia.